Keun Seok Lee on Muck Rack

Keun Seok Lee

As seen in: Nature, MDPI, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Keun Seok

Contact Keun Seok, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer

|
By Sung Hoon Sim, Keun Seok Lee, Korea College, Su Yeon Jeon
| Nature Verified
Abstract We prospectively evaluated the utility of ESR1 and PIK3CA mutation analysis with cell-free DNA (cfDNA) using droplet digital PCR (ddPCR) for the efficacy of endocrine therapy (ET) in hormone receptive positive (HR+) metastatic breast cancer (MBC) patients. CfDNA was analyzed just before the start of ET for MBC. E380Q, Y537N, Y537S, and D538G were assessed for ESR1 mutations and H1047R, E545K, and E542K were assessed for PIK3CA mutations. A total of 75 patients were enrolled.
Open in Who Shared Issue with article?

A Phase Ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer

|
By Yen-Shen Lu, Keun Seok Lee, Ling-Ming Tseng, Tsu-Yi Chao
| AACR Journal
Research Article Yen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, Ling-Ming Tseng, Imjai Chitapanarux, Shin-Cheh Chen, Chien-Ting Liu, Joohyuk Sohn, Jee Hyun Kim, Yuan-Ching Chang, Youngsen Yang, Kanjana Shotelersuk, Kyung Hae Jung, Roberta Valenti, Cassandra Slader, Melissa Gao and Yeon Hee Park DOI: 10.1158/1078-0432.CCR-20-1008 Abstract Purpose: This study reports the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of alpelisib or buparlisib used in...
Open in Who Shared Issue with article?

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncolog

|
By Stephen Albert Johnston, Angelo Di Leo, Keun Seok Lee
| The Lancet Verified
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified